Compare Marriott International Inc (MAR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Recursion Pharmaceuticals Inc — how do they compare? Marriott International Inc trades at $366.01 (market cap $94.16B), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Marriott International Inc is far larger — about 44× Recursion Pharmaceuticals Inc's market cap, and Marriott International Inc pays a 0.81% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| MAR | RXRX | |
|---|---|---|
Market Cap | $94.16B | $2.14B |
Volume | 996,176 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $6.79 |
52-Week Low | $259.04 | $2.84 |
Typical Hold Time | 164 Days | 23 Days |
Enterprise Value | $111.47B | $1.66B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $363.49, up 1.96% today, showing strong momentum near resistance at $364. The stock maintains a bullish technical outlook with positive moving averages and ADX signals. Fundamentally, revenue grew to $26.19B in 2025 with a 9.62% net margin, though valuation metrics appear elevated with a P/E of 37.38. Recent earnings beat expectations in Q1 and Q2 2026, while analysts maintain a consensus price target of $386.71 with 44% buy ratings.
Outlook remains positive driven by travel demand recovery and strategic partnerships, but risks include rising debt levels (debt-to-asset ratio at 58.83% in 2025) and economic sensitivity. The stock offers moderate upside to analyst targets with institutional confidence, though high valuation requires sustained earnings growth to justify current levels.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
